Zacks Small Cap Research – SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… – Go Health Pro
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte in patients with … Read more
